---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References"
description: "Reference list for the formulary evidence report on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy. 143 cited documents."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References

<a id="references"></a>

## 5 References

1. [Adrichem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166547/)
2. [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/)
3. [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)
4. [Allen and Lewis (2015)](https://pubmed.ncbi.nlm.nih.gov/26180143/)
5. [Allen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29053880/)
6. [Allen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32338716/)
7. [Allen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854453/)
8. [Allen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39304241/)
9. [Allen et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375598/)
10. [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)
11. [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)
12. [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)
13. [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)
14. [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)
15. [argenx annual report (2026)](https://reports.argenx.com/2025/argenx-group/our-products-and-product-candidates/empasiprubart-development.html)
16. [Bamrungsawad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27113227/)
17. [Blackhouse et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2903512/)
18. [Blein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12896209/)
19. [Brackx et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13368673/)
20. [Breiner et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24723454/)
21. [Bril et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37314318/)
22. [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)
23. [Broers et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8252611/)
24. [Bus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10865446/)
25. [Bus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13459082/)
26. [CDA-AMC efgartigimod alfa reimbursement recommendation (2026)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/SR0894/2990?inline=1)
27. [CDA-AMC efgartigimod alfa reimbursement review (2026)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0894r/3193?inline=1)
28. [Choi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11390450/)
29. [ClinicalTrials.gov NCT04281472](https://clinicaltrials.gov/study/NCT04281472?tab=results)
30. [ClinicalTrials.gov NCT06290128](https://clinicaltrials.gov/study/NCT06290128)
31. [ClinicalTrials.gov NCT06290141](https://clinicaltrials.gov/study/NCT06290141)
32. [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)
33. [ClinicalTrials.gov NCT06920004](https://clinicaltrials.gov/study/NCT06920004)
34. [ClinicalTrials.gov NCT07091630](https://clinicaltrials.gov/study/NCT07091630)
35. [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)
36. [Cook et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10098814/)
37. [Cornblath et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9050528/)
38. [Dalakas (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294117/)
39. [De Lorenzo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11235819/)
40. [de Pedro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13000016/)
41. [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)
42. [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)
43. [Dianthus Therapeutics (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024123255/dnth-ex99_1.htm)
44. [Dianthus Therapeutics (2025a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/dnth-ex99_1.htm)
45. [Dianthus Therapeutics (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm)
46. [Dianthus Therapeutics (2026e)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-ex99_1.htm)
47. [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)
48. [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)
49. [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)
50. [Dianthus Therapeutics Form 10-Q (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000022/dnth-20260331.htm)
51. [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)
52. [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)
53. [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)
54. [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)
55. [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)
56. [Dianthus Therapeutics presentation (2026b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_3.htm)
57. [Dianthus Therapeutics presentation (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-ex99_1.htm)
58. [Dianthus Therapeutics presentation (2026d)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-ex99_1.htm)
59. [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)
60. [Divino et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6198979/)
61. [Draak et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25378677/)
62. [Dyck et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3511382/)
63. [Eftimov et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22442436/)
64. [EU Clinical Trials Information System 2024-517529-26-00](https://euclinicaltrials.eu/ctis-public/view/2024-517529-26-00)
65. [Figueroa et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3306161/)
66. [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)
67. [Gammagard Liquid prescribing information (2024)](https://www.fda.gov/media/191699/download)
68. [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)
69. [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)
70. [Guptill et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24639235/)
71. [Guptill et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6611518/)
72. [Guptill et al. (2024)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/136957)
73. [Hadden et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4286942/)
74. [Hadden et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625974/)
75. [Hafsteinsdottir and Olafsson (2016)](https://pubmed.ncbi.nlm.nih.gov/27211228/)
76. [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/)
77. [Hauw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34060689/)
78. [Hizentra prescribing information (2021)](https://www.fda.gov/media/78466/download)
79. [Hughes et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11506402/)
80. [Hughes et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18178525/)
81. [Hughes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6747552/)
82. [HyQvia prescribing information (2026)](https://www.fda.gov/media/89844/download)
83. [Jung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10622719/)
84. [Katzberg et al. (2024)](https://investor.dianthustx.com/static-files/f8df567c-6c87-4c24-9195-34850953731f)
85. [Koay et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11836592/)
86. [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)
87. [Layton et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10310640/)
88. [Léger et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3910165/)
89. [Lemmen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11915482/)
90. [Mahdi-Rogers et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6481566/)
91. [Mallick et al. (2025)](https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-002929.html)
92. [Marsh et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33106368/)
93. [McCrone et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14641514/)
94. [Mehndiratta et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6734114/)
95. [Mengel et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30073683/)
96. [Merkies et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10951442/)
97. [Merkies et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19365055/)
98. [Michaelides et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6857093/)
99. [Min et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11628630/)
100. [Muley et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42764727/)
101. [Murakami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456398/)
102. [NICE ID6409 draft guidance (2026)](https://www.nice.org.uk/guidance/gid-ta11508/documents/draft-guidance-2)
103. [NICE ID6409 project information (2026)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11508)
104. [Nobile-Orazio et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22578914/)
105. [Nobile-Orazio et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11967823/)
106. [Nowacek et al. (2025)](https://www.mdaconference.org/abstract-library/employment-daily-activities-and-caregiver-burden-in-cidp-results-of-a-real-world-us-survey/)
107. [Okonkwo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40025632/)
108. [Pallada et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13691695/)
109. [Panzyga prescribing information (2021)](https://www.fda.gov/media/115397/download)
110. [Pasangulapati et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5586124/)
111. [Pasnoor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006664/)
112. [Privigen prescribing information (2025)](https://www.fda.gov/media/83304/download)
113. [Querol et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8463372/)
114. [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)
115. [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)
116. [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)
117. [Querol et al. (2026d)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-000633.html)
118. [Quint et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11377626/)
119. [Rajabally and Cavanna (2015)](https://pubmed.ncbi.nlm.nih.gov/25467139/)
120. [Rajabally et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12529031/)
121. [RMC Trial Group (2009)](https://pubmed.ncbi.nlm.nih.gov/19136303/)
122. [Rumsey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540753/)
123. [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444)
124. [Sommer et al. (2026)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-002025.html)
125. [Stascheit et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12449320/)
126. [Stascheit et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12794542/)
127. [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)
128. [van Doorn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10875175/)
129. [van Doorn et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13434837/)
130. [van Nes et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21263135/)
131. [van Schaik et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20133204/)
132. [van Schaik et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4960813/)
133. [van Schaik et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29122523/)
134. [van Schaik et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6624149/)
135. [Vanhoutte et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/22891893/)
136. [Vissing et al. (2024)](https://investor.dianthustx.com/static-files/0ec7e0cd-6d44-419f-b020-01f204c56da3)
137. [Vu et al. (2026b)](https://investor.dianthustx.com/static-files/2aa268f8-9efe-4897-b3e9-5c576d4f94bc)
138. [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)
139. [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L04AJ)
140. [WHO Drug Information Recommended INN List 94 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl94.pdf)
141. [WHO INN monoclonal antibody nomenclature scheme (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/new_mab_nomenclature-_2021rev.pdf)
142. [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)
143. [Yang et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396306/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
